Latest Industry Insights

Biological complexity is not getting any easier to unravel but utilizing the power of computers could make us better at it.

A receptor (drug target) can shift from a single subunit to a multi-structure in the presence of a ligand (drug compound) – a process known as "oligomerization". Now, using photon excitation microscopy, researchers report that they can uncover the various protein receptor oligomers formed in the absence or presence of different drug candidates that bind to them.

Aided by advances in high-throughput technologies, the metabolomics research field has gained significant traction. We spoke with Baljit Ubhi, Ph.D. from SCIEX, about the recent developments in metabolomics, addressing the increasing focus on the microbiome, how it impacts metabolic disease, and the future directions of research, including "precision nutrition".

Megatrends are overarching trends, ones that seed and embrace multiple market and technology developments. These trends already exist in our world today but are going to be even more important in the years to come. Here we highlight three technology megatrends that could be highly significant to our future.

A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.

As scientists, we’re often subjected to certain stereotypes. We’re assumed to be smart and nerdy; we work long hours, wear lab coats, and obsess over data. Some or all of these traits and behaviors may ring true at a population level, but for individual scientists they don’t always stack up. The same disconnect applies to cells. We assume that the average phenotype is representative of all of the members of a population, but too often it is not...

Technology Networks recently visited Dresden, Germany, for Lipotype's Lipid Excellence Award press talk, where we gained insights into the past, present and future of lipidomics research.

We recently had the pleasure of speaking with David Younger, PhD., Co-founder and CEO of A-Alpha Bio, to learn more about AlphaSeq – a platform designed to measure millions of protein–protein interactions simultaneously.

Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.